Shelton, Connecticut Thursday, July 17, 2025, 18:00 Hrs [IST] ...

NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage innovator in broad-spectrum antivirals, announced near-finalization of its adaptive clin ...

Randomized sub-trial 1 of a global adaptive platform trial of COM701 maintenance therapy in patients with relapsed platinum sensitive ovarian cancer Trial supported by strong ...

Artificial Intelligence (AI) is no longer just a buzzword it is transforming the way healthcare is delivered and its influence is now reaching deep into the world of clinical trials from predicting ...

Moleculin Biotech, Inc. 40+ year career at Roche founded on dedication to bringing new innovative medicines to patients and ...

As biopharma innovation becomes increasingly data-driven and autonomous, the integration of Chinese AI- renowned for rapid ...

In early research, OCU410ST, a gene therapy for Stargardt disease, demonstrated slowed lesion growth by 48% at the 12-month follow-up in evaluable treated eyes.

For decades, Alzheimer’s disease has resisted nearly every significant pharmaceutical intervention. Despite billions invested ...

Dementia associated with Alzheimer’s disease is a progressive neurodegenerative condition characterized by memory loss, cognitive decline, and impaired daily functioning. The growing aging population ...

This year, the EHA Congress provided us with long-term follow-up of some very interesting study, including the GAIA/CLL13 ...

Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

Graham Clark, CEO, Phastar, explores the current state of play in clinical research, the future of AI in the field and values-based business.